|
1）Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336: 177-8
|
|
|
|
2）Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000; 43: 1982-93
|
|
|
|
|
3）Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990; 74: 1-9
|
|
|
|
|
|
4）Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306
|
|
|
|
|
|
5）Cervera R, Boffa MC, Khamashta MA, et al. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009; 18: 889-93
|
|
|
|
|
|
6）Harris EN. Antiphospholipid syndrome. Br J Haematol. 1990; 74: 1-9
|
|
|
|
|
|
7）Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999; 42: 1309-11
|
|
|
|
|
|
8）Uthman I, Godeau B, Taher A, et al. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev. 2008; 22: 187-94
|
|
|
|
|
|
9）Atsumi T, Furukawa S, Amengual O, et al. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus. 2005; 14: 499-504
|
|
|
|
|
|
10）家子正裕，内藤澄悦，吉田美香，他．抗リン脂質抗体症候群の病態と診断－特に抗リン脂質抗体と血小板について－．日本検査血液学会．2009; 10: 251-7
|
|
|
|
|
|
11）Diz-Küçükkaya R, Hacihanefioğlu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001; 98: 1760-4
|
|
|
|
|
|
12）蔵本 淳．特発性血小板減少性紫斑病分科会報告．厚生省特定疾患「特発性造血障害」調査研究班 平成2年度研究業績報告書．1991; p59-63
|
|
|
|
|
|
13）Jy W, Tiede M, Bidot CJ, et al. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res. 2007; 121: 319-25
|
|
|
|
|
|
14）Bontadi A, Ruffatti A, Falcinelli E, et al. Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thromb Haemost. 2013; 109: 901-8
|
|
|
|
|
|
15）Urbanus RT, Pennings MT, Derksen RH, et al. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibα and apolipoprotein E receptor 2ʼ. J Thromb Haemost. 2008; 6: 1405-12
|
|
|
|
|
|
16）Vlachoyiannopoulos PG, Routsias JG. A novel mechanism of thrombosis in antiphospholipid antibody syndrome. J Autoimmun. 2010; 35: 248-55
|
|
|
|
|
|
17）Lin YL, Wang CT. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood. 1992; 80: 3135-43
|
|
|
|
|
|
18）Hulstein JJ, Lenting PJ, de Laat B, et al. beta2-glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood. 2007; 110: 1483-91
|
|
|
|
|
|
19）de Mesquita HL, de Carvalho GR, Aarestrup FM, et al. Evaluation of platelet aggregation in the presence of antiphospholipid antibodies: anti-β2GP1 and anticardiolipin. Rev Bras Reumatol. 2013; 53: 400-4
|
|
|
|
|
|
20）Schallmoser K, Rosin C, Vormittag R, et al. Specificities of platelet autoantibodies and platelet activation in lupus anticoagulant patients: a relation to their history of thromboembolic disease. Lupus. 2006; 15: 507-14
|
|
|
|
|
|
21）Godeau B, Piette JC, Fromont P, et al. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol. 1997; 98: 873-9
|
|
|
|
|
|
22）Proulle V, Furie RA, Merrill-Skoloff G, et al. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood. 2014; 124: v611-22
|
|
|
|
|